Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on immunology that reached public markets through a SPAC combination in the early 2020s. The company filed a Form 10-Q with the Securities and Exchange Commission on May 16, 2022, providing a quarterly operational update as a reporting public company in the healthcare and life sciences sector. Estrella is engaged in developing novel immunological therapies, positioning itself within a cohort of biopharma companies that utilized the blank-check vehicle to access capital markets. Investors and analysts seeking full filing history, sponsor details, and deal data for ESLA can sign up for complete coverage on SpacDesk.